Complementary Cardioprotection and Efferocytosis by Circulating Vesicle Recruitment and SIRPα Blockade after Myocardial Ischemia/Reperfusion
Year: 2026
Type: article
Abstract: Acute myocardial infarction (AMI) causes heart failure and mortality, driven by ischemia/reperfusion (I/R) injury and CD47/Signal regulator protein α (SIRPα)-impaired efferocytosis that together sustain tissue damage. Endogenous plasma small extracellular vesicles (P-EVs) offer an endogenous, multifunctional option, yet their cardioprotective efficacy is limited by low cardiac accumulation. Herein, a nanosystem (SαV-DAb) was developed by functionalizing SIRPα-variant-overexpressing nanovesicles (SαV) with dual antibodies (DAb) against CD42b (platelet marker) and CD63 (EV marker) via a reactive oxygen species (ROS)-cleavable linkage. This configuration allows the nanovesicles to hitchhike on circulating platelets for targeted delivery to the ischemic heart, while simultaneously capturing and enriching protective circulating P-EVs in the lesion. SαV could bind to CD47, avoiding the SIRPα activation on macrophages and promoting efferocytosis. SαV-DAb demonstrated significantly enhanced cardiac accumulation and promoted targeted delivery of P-EVs to the ischemic myocardium. Treatment with SαV-DAb elicited a coordinated therapeutic response, including anti-apoptosis, pro-angiogenesis, and pro-efferocytosis, ultimately leading to attenuated ventricular fibrosis and improved systolic function after I/R injury, with no observable toxicity. This strategy simplifies the preparation workflow by avoiding prior isolation of PLTs and protective vesicles, and provides a conceptual framework for endogenous-system-based nanomedicine in cardiac repair.
Source: Advanced Science
DOI: 10.1002/advs.78697
Authors: Qi Pan(Conceptualization, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft), Ye Zhu(Conceptualization, Formal analysis, Investigation, Methodology, Software, Validation), Ziqin Zhou(Conceptualization, Visualization), Yao Jiang(Methodology, Software), Yuejin Yang(Methodology, Resources, Software), Ling Yu(Funding acquisition, Methodology, Writing – review & editing), Yuanwei Pan(Conceptualization, Data curation, Funding acquisition, Project administration, Resources, Supervision, Visualization, Writing – review & editing), Guihao Chen(Conceptualization, Data curation, Funding acquisition, Project administration, Resources, Software, Supervision, Writing – review & editing)
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Fu Wai Hospital, State Key Laboratory of Cardiovascular Disease, Chinese University of Hong Kong, Shenzhen Bay Laboratory, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University, Guangdong Provincial Hospital of Chinese Medicine, Nanchang University
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,730
Awards: G488099362, G6827307684, G9000357668
OpenAlex ID: W7234035062
